Supplemental Figure 6 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in <i>pdgfra D842V</i>-Mutant Gastrointestinal Stromal Tumor

Ferdinand Rossi,Mengyuan Liu,Andrew Tieniber,Mark S. Etherington,Andrew Hanna,Gerardo A. Vitiello,Nesteene J. Param,Kevin Do,Laura Wang,Cristina R. Antonescu,Shan Zeng,Jennifer Q. Zhang,Ronald P. DeMatteo

crossref（2023）

引用 0|浏览7

暂无评分

摘要

Supplemental Figure 6.Cell survival of GIST T1 cells treated with imatinib or avapritinib for 72h in complete media.Each data point represents an average of 10 wells.

查看译文

关键词

Imatinib Mesylate

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

Supplemental Figure 6 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in &lt;i&gt;pdgfra D842V&lt;/i&gt;-Mutant Gastrointestinal Stromal Tumor

Supplemental Figure 6 from Myosin Light-Chain Kinase Inhibition Potentiates the Antitumor Effects of Avapritinib in <i>pdgfra D842V</i>-Mutant Gastrointestinal Stromal Tumor